Unisys Announces 3Q25 Results
Unisys reiterates full-year non-GAAP operating profit margin guidance and advances pension strategy with annuity purchase transaction Total company revenue of $460.2... Read more.
Hon Tony Abbott AC Joins Rivada Networks Board of Directors
WASHINGTON, Nov. 5, 2025 /PRNewswire/ — Rivada Networks, the developer and operator of the Outernet, has named the Honorable Tony Abbott, the 28th prime minister... Read more.
StemCyte Launches First Insurance-Linked Public Cord Blood Access in Taiwan, Setting a New Standard in Cell Therapy Protection
BALDWIN PARK, Calif., Nov. 5, 2025 /PRNewswire/ — StemCyte International (TPEX: 4178), a global leader in cord blood banking and cell therapy, today announced... Read more.
Miami International Holdings Reports Results for Third Quarter 2025
Net revenue grew 57% year-over-year to $109.5 million GAAP net loss of $102.1 million, impacted by one-time loss on extinguishment of debt and IPO-related expenses... Read more.
Global IoT Antenna Shipments to Reach 13 Billion by 2030 Despite Lingering Post-Pandemic Headwinds
NEW YORK, Oct. 30, 2025 /PRNewswire/ — Wordwide IoT antenna shipments are projected to recover to 13 billion units by 2030, according to global technology... Read more.
Lucid Announces Organizational Changes to Accelerate Growth, Optimize Decision-Making and Strengthen Global Expansion
NEWARK, Calif., Nov. 5, 2025 /PRNewswire/ — Lucid Group, Inc. (NASDAQ: LCID), maker of the world’s most advanced electric vehicles, today announced... Read more.
Caris Life Sciences Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
Revenue growth of 113% driven by strong performance in molecular profiling services Raises 2025 revenue guidance to $720 to $730 million, representing year-over-year... Read more.
Resideo Announces Third Quarter 2025 Financial Results
Third quarter net revenue of $1.86 billion, up 2% year-over-year; ADI and Products & Solutions (“P&S”) each grew net revenue 2% year-over-year... Read more.
Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights
– Dosed first patients with dabogratinib in BEACH301 and SURF302; interim results from both studies expected in 2026 – – Expanded development of... Read more.
Talphera to Host Third Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, November 12, 2025
SAN MATEO, Calif., Nov. 5, 2025 /PRNewswire/ — Talphera, Inc. (Nasdaq: TLPH), (“Talphera”), a specialty pharmaceutical company focused on the development... Read more.